THERAPY DOSSIER · th-19512fa87d6f

Hepatocyte growth factor (HGF)

Biologic

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Endotoxin/LPS
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 25539852 ↗2014Reported benefit

Asef mediates HGF protective effects against LPS-induced lung injury and endothelial barrier dysfunction.

MixedEndotoxin/LPSAsef knockout mice and wild-type controls

Model: Lipopolysaccharide-induced acute lung injury and pulmonary endothelial barrier dysfunction

HGF protected the pulmonary endothelial monolayer against LPS-induced hyperpermeability, NF-kB activation, adhesion molecule expression and IL-8 production. These effects depended on Asef, since Asef knockdown and Asef knockout mice showed diminished HGF protection against lung inflammation and vas…

Extraction: extract · Supplied extraction confidence: 0.6. Machine-extracted fields require source verification.

Loading the evidence…